87 related articles for article (PubMed ID: 17117416)
1. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.
Osorio S; Noblejas AG; Durán A; Steegmann JL
Am J Hematol; 2007 May; 82(5):394-5. PubMed ID: 17117416
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.
Hahn EA; Glendenning GA; Sorensen MV; Hudgens SA; Druker BJ; Guilhot F; Larson RA; O'Brien SG; Dobrez DG; Hensley ML; Cella D;
J Clin Oncol; 2003 Jun; 21(11):2138-46. PubMed ID: 12775739
[TBL] [Abstract][Full Text] [Related]
3. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
4. Imatinib and beyond--the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/low-dose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia.
Berger U; Engelich G; Reiter A; Hochhaus A; Hehlmann R;
Ann Hematol; 2004 Apr; 83(4):258-64. PubMed ID: 14648019
[No Abstract] [Full Text] [Related]
5. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Deininger MW; Cortes J; Paquette R; Park B; Hochhaus A; Baccarani M; Stone R; Fischer T; Kantarjian H; Niederwieser D; Gambacorti-Passerini C; So C; Gathmann I; Goldman JM; Smith D; Druker BJ; Guilhot F
Cancer; 2007 Oct; 110(7):1509-19. PubMed ID: 17702093
[TBL] [Abstract][Full Text] [Related]
6. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
7. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
Ram R; Gafter-Gvili A; Okon E; Pazgal I; Shpilberg O; Raanani P
Acta Haematol; 2008; 119(2):104-7. PubMed ID: 18367829
[TBL] [Abstract][Full Text] [Related]
8. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H; Coppo P; Hayman JP; Fouqueray B; Mougenot B; Ronco P
Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
[TBL] [Abstract][Full Text] [Related]
9. [Prognosis factors in imatinib mesilate therapy in patients with a chronic phase of Ph-positive chronic myeloid leukemia: data from a multicenter non-randomized trial in Russia].
Zaritskiĭ AIu; Lomaia EG; Vinogradova OIu; Druzhkova GA; Kolosheĭnova TI; Loria SS; Pospelova TI; Krylova IV; Kruglov SS; Kuznetsov SV; Chelysheva EIu; Abakumov EM; Sokolova MA; Nemchenko IS; Zakharova ES; Goriacheva SR; Kolosova LIu; Vakhrusheva MV; Liamkina AS; Chernova OA; Machiulaĭtene ER; Ivanova VL; Udal'eva VIu; Shneĭder TV; Ogorodnikova IuS; Zhuravlev VS; Zakharova AV; Martynkevich IS; Domracheva EV; Afanas'ev BV; Abdulkadyrov KM; Kovaleva LG; Khoroshko ND; Turkina AG
Ter Arkh; 2007; 79(8):17-22. PubMed ID: 17926465
[TBL] [Abstract][Full Text] [Related]
10. [Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects].
Zou WY; Xu DR; Su C; Li J; Luo SK
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1660-2. PubMed ID: 18819894
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients.
Kobayashi S; Kimura F; Kobayashi A; Sato K; Motoyoshi K
Ann Hematol; 2009 Apr; 88(4):311-5. PubMed ID: 18704417
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy of imatinib mesylate for 124 patients with chronic myeloid leukemia in accelerated and blastic phase].
Jiang Q; Chen SS; Jiang B; Jiang H; Qiu JY; Liu YR; Zhang Y; Qin YQ; Lu Y; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):721-6. PubMed ID: 18457260
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience.
Bee PC; Gan GG; Teh A; Haris AR
Med J Malaysia; 2006 Dec; 61(5):547-52. PubMed ID: 17623954
[TBL] [Abstract][Full Text] [Related]
14. Imatinib use during pregnancy and breast feeding: a case report and review of the literature.
Ali R; Ozkalemkas F; Kimya Y; Koksal N; Ozkocaman V; Gulten T; Yorulmaz H; Tunali A
Arch Gynecol Obstet; 2009 Aug; 280(2):169-75. PubMed ID: 19083009
[TBL] [Abstract][Full Text] [Related]
15. Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate.
Ferraresi V; Catricalà C; Ciccarese M; Ferrari A; Zeuli M; Cognetti F
Anticancer Res; 2006; 26(6C):4771-4. PubMed ID: 17214339
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.
Sillaber C; Mayerhofer M; Böhm A; Vales A; Gruze A; Aichberger KJ; Esterbauer H; Pfeilstöcker M; Sperr WR; Pickl WF; Haas OA; Valent P
Eur J Clin Invest; 2008 Jan; 38(1):43-52. PubMed ID: 18173550
[TBL] [Abstract][Full Text] [Related]
17. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
[TBL] [Abstract][Full Text] [Related]
18. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
[TBL] [Abstract][Full Text] [Related]
19. Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Atallah E; Cortes J
Curr Opin Hematol; 2007 Mar; 14(2):138-44. PubMed ID: 17255791
[TBL] [Abstract][Full Text] [Related]
20. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase.
Kiguchi T; Tauchi T; Ito Y; Miyazawa K; Kimura Y; Ohyashiki K
Leuk Res; 2009 Mar; 33(3):506-8. PubMed ID: 18533259
[No Abstract] [Full Text] [Related]
[Next] [New Search]
